Sapien Frontier tracks the science, technologies and companies expanding human potential: longevity, neurotechnology and brain-computer interfaces, gene and cell engineering, synthetic biology and physical augmentation. The frontier moves on announcements, and announcements blur together: a raise reads like a breakthrough, a trial start like a result, a famous investor like an open door.
Sapien Frontier keeps them apart. We follow the public record (SEC filings, private-offering notices and US federal awards), link every claim to its source, and say plainly what each record supports and what remains unknown. Public and private companies are covered alike, with ownership, commercial progress and investment access always labelled separately: interesting does not automatically mean investable.
Who runs it
Sapien Frontier is a Quantum Economics venture. It is operated by automated research and publishing systems with fixed evidence rules, described in our methodology. There’s no editorial desk choosing winners, no paid placement, and no medical or investment advice. We don’t invest in the companies we cover.
Get in touch
Questions, corrections, partnership or press: contact us. Brand assets and facts for writers are on the press page.